Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)-Reference-Cited by-同舟云学术

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

Published:2019-06-21 Issue:1 Volume:20 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Jensen Jesper^ORCID,Omar Massar,Kistorp Caroline,Poulsen Mikael Kjær,Tuxen Christian,Gustafsson Ida,Køber Lars,Gustafsson Finn,Fosbøl Emil,Bruun Niels Eske,Videbæk Lars,Frederiksen Peter Hartmund,Møller Jacob Eifer,Schou Morten

Funder

the Research Council at Herlev-Gentofte Hospital

FUKAP at the Department of Cardiology at Herlev-Gentofte Hospital

the Capital Region of Denmark

the Danish Heart Foundation

the A.P. Møller Foundation for the Advancement of Medical Science

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-019-3474-5.pdf

Reference42 articles.

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

2. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.

3. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

4. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249–59.

5. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018;71(23):2628–39.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health status;American Heart Journal;2024-12

2. SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure;JAMA Network Open;2024-04-04

3. Decongestion in Acute Heart Failure—Time to Rethink and Standardize Current Clinical Practice?;Journal of Clinical Medicine;2024-01-05

4. Medical Treatment in Heart Failure with Reduced Ejection Fraction: A Proposed Algorithm Based on the Patient’s Electrolytes and Congestion Status;Medical Sciences;2023-05-24

5. Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial;American Heart Journal Plus: Cardiology Research and Practice;2023-02